Insulet Co. (NASDAQ:PODD) hit a new 52-week high during trading on Wednesday . The stock traded as high as $155.62 and last traded at $153.98, with a volume of 445727 shares traded. The stock had previously closed at $152.43.

Several research analysts have commented on the company. JPMorgan Chase & Co. raised Insulet from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $120.00 to $155.00 in a research report on Tuesday, August 6th. Raymond James lifted their price target on Insulet from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 6th. Guggenheim lifted their price target on Insulet from $100.00 to $145.00 and gave the stock a “positive” rating in a research report on Tuesday, August 6th. BidaskClub raised Insulet from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Finally, ValuEngine downgraded Insulet from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $131.71.

The firm has a market capitalization of $9.19 billion, a P/E ratio of 3,079.60 and a beta of 1.08. The company has a quick ratio of 3.91, a current ratio of 4.72 and a debt-to-equity ratio of 2.43. The business has a 50-day moving average price of $129.90 and a 200-day moving average price of $106.10.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Monday, August 5th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $177.10 million for the quarter, compared to the consensus estimate of $163.63 million. Insulet had a net margin of 2.66% and a return on equity of 7.85%. The business’s revenue for the quarter was up 42.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. As a group, sell-side analysts forecast that Insulet Co. will post 0.26 EPS for the current year.

In related news, insider Shacey Petrovic sold 895 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $113.00, for a total value of $101,135.00. Following the sale, the insider now owns 95,559 shares of the company’s stock, valued at approximately $10,798,167. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Sally Crawford sold 28,347 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $108.60, for a total value of $3,078,484.20. Following the completion of the sale, the director now directly owns 28,469 shares in the company, valued at approximately $3,091,733.40. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.

A number of hedge funds have recently made changes to their positions in PODD. Manchester Capital Management LLC acquired a new position in Insulet in the first quarter worth $31,000. Advisors Preferred LLC acquired a new position in Insulet in the second quarter worth $38,000. Harvest Fund Management Co. Ltd acquired a new position in Insulet in the second quarter worth $43,000. Meridian Wealth Management LLC acquired a new position in Insulet in the first quarter worth $48,000. Finally, Quadrant Capital Group LLC boosted its stake in Insulet by 1,037.7% in the first quarter. Quadrant Capital Group LLC now owns 603 shares of the medical instruments supplier’s stock worth $55,000 after purchasing an additional 550 shares in the last quarter.

Insulet Company Profile (NASDAQ:PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

See Also: What does a hold rating mean?

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.